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Purpose: The purpose of this work was to investigate the dosimetric impact of
mixed energy (6‐MV, 15‐MV) partial arcs (MEPAs) technique on prostate cancer
VMAT plans.
Methods: This work involved prostate only patients, planned with 79.2 Gy in 44
fractions to the planning target volume (PTV). Femoral heads, bladder, and rectum
were considered organs at risk. This study was performed in two parts. For each of
the 25 patients in Part 1, two single‐energy single‐arc plans, a 6 MV‐SA plan and a
15 MV‐SA plan, and a third MEPA plan involving composite of 6‐MV anterior–pos-
terior partial arcs and a 15‐MV lateral partial arc weighted 1:2 were created. The
dosimetric difference between MEPA(6/15 MV 1:2 weighted) and 6 MV‐SA plans,
and MEPA(6/15 MV 1:2 weighted) and 15 MV‐SA plans were measured. In the Part
2 of this study, a second MEPAs plan (6 MV anterior–posterior arcs and 15 MV lat-
eral arcs weighted 1:1), (MEPA 6/15 MV 1:1 weighted), was generated for 15
patients and compared only with two single‐energy partial arcs plans, a 6 and a
15 MV‐PA, to investigate the inﬂuence of the energy only. Dosimetric parameters
of each structure, total monitor‐units (MUs), homogeneity index (HI), and conformity
number (CN) were analyzed.
Results: In Part 1, no statistically signiﬁcant differences were observed for mean
dose to PTV and CN for MEPAs (6/15 MV 1:2 weighted) vs 6 and 15 MV‐SA.
MEPAs (6/15 MV 1:2 weighted) increased HI compared to 6 and 15 MV‐SA
(P < 0.0005; P < 0.0005). MEPAs (6/15 MV 1:2 weighted) produced signiﬁcantly
lower mean doses to rectum, bladder, and MUs/fraction, but higher mean doses to
femoral heads, compared to 6 MV‐SA (P < 0.0005) and 15 MV‐SA (P < 0.0005).
The results of Part 2 of this study showed that, in comparison to 6 and 15 MV‐PA,
MEPAs (6/15 MV 1:1 weighted) plans signiﬁcantly improved CNs (P < 0.0005;
P < 0.0005) and produced signiﬁcantly lower mean doses to the rectum and bladder
(P < 0.0005; P < 0.0005). While mean doses to the PTV and femoral heads of
MEPAs (6/15 MV 1:1 weighted) plans were statistically comparable to 6 MV‐PA
(P > 0.05), MEPAs (6/15 MV 1:1 weighted) increased mean doses to left (P = 0.04)
and right (P = 0.04) femoral heads compared to 15 MV‐PA. MEPAs (6/15 MV 1:1
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weighted) resulted in signiﬁcantly lower total MUs compared to 6 MV‐PA
(P < 0.0005) and 15 MV‐PA (P = 0.04).
Conclusion: The study for prostate radiotherapy demonstrated that a choice of
MEPAs for VMAT has the potential to minimize doses to OARs and improve dose
conformity to PTV, at the expense of a moderate increase in mean dose to the
femoral heads.
K E Y WORD S
mixed energy VMAT, optimization, treatment planning
1 | INTRODUCTION
The main goal of radiation therapy is to provide dose conformity to the
target in four dimensions of space and time while minimizing the dose
to the normal tissues and organs at risk. Early techniques used geomet-
ric ﬁeld shaping alone involving blocks or multileaf collimators (MLC) to
conform to the target volume. Subsequently, intensity modulated radia-
tion therapy (IMRT) allowed modulation of ﬂuence across the geometri-
cally shaped ﬁeld by using multiple radiation beams of nonuniform
intensities. Currently, IMRT is widely practiced in clinics owing to its
dosimetric advantages such as superior target dose conformity and bet-
ter OARs sparing.1 During the last decade, volumetric modulated arc
therapy (VMAT) using modulated arcs is gaining popularity due to its
improved efﬁciency compared to IMRT. VMAT involves the simultane-
ous rotational movement between the linear accelerator along with
varying dose rate, gantry speed, and the shaping of multileaf collimator
(MLC) leaves to produce modulated ﬂuence while the beam is on. It has
been reported by a number of studies that VMAT results in improved
delivery efﬁciency than IMRT for various types of cancer.2–7 A compre-
hensive meta‐analysis on preferred technique in prostate treatment has
shown that, in addition to improvement in the delivery efﬁciency,
VMAT also protects OARs better than IMRT for prostate cancer.8
Both IMRT and VMAT utilize inverse planning algorithms for opti-
mization of dose to target and OARs. A clinically available optimization
software optimizes ﬂuence map for each beam angle to achieve dose‐
volume objectives. However, it does not optimize for couch angle or
photon energy. The selection of these parameters depends on the
tumor location and the experience of a treatment planner. The prefer-
ence on selection of photon beam energy for deep seated targets var-
ies due to various energy‐related dosimetric consequences. For
instance, use of low energy photon beams (≤6 MV) generates narrow
penumbra, which results in tighter dose distribution around the target.
However, for deep seated targets, it may result in a higher surface
dose. Higher energy photon beams, on the other hand, increase for-
ward scattering of electrons and photons, resulting in a low skin dose,
but may result in undesirable dose to the patient from secondary neu-
trons (especially for 18 MV). A number of previous studies for prostate
cancer reported dosimetric beneﬁts of using a higher energy photon
beam over 6 MV photon beam.9–12
Only a handful of studies, however, have compared dosimetric
results of mixed energy (both low and high MV) IMRT plans with a
single energy IMRT for deep seated targets.12,13 While Park et al.12
performed a sequential optimization of photon beam energy (i.e.,
generation of 6 MV ﬂuence maps followed by 15 MV ﬂuence maps)
using a commercial treatment‐planning software, McGeachy et al.13
performed simultaneous optimization of photon beam energy and
ﬂuence maps using an external optimizer. Nonetheless, both studies
showed that mixed energy IMRT improved overall quality of the
treatment plans including better sparing of OARs.
To our knowledge, for VMAT, only one study has investigated
the dosimetric inﬂuence of mixed energy VMAT approach for pros-
tate cancer.14 Pokharel compared the mixed energy full arcs VMAT
plans (a composite of 6 MV primary plan and 16 MV boost plan) with
a single‐energy full arcs VMAT plans of either low or high energy.
Pokharel reported mixed energy VMAT plans to be superior over a
single‐energy VMAT plans in better sparing of OARs while maintain-
ing dose conformity to the target. Since the current commercial
VMAT optimizers are not capable of optimizing a single plan with
more than one energy, a mixed energy VMAT plan can only be cre-
ated by combining two or more individual plans.15 In this work, we
created mixed energy partial arcs (MEPAs) plans by manually merging
a 6 MV partial arcs plan and a 15 MV partial arcs plan. To our knowl-
edge, the investigation on the dosimetric impacts of MEPAs on
VMAT plans for prostate has not been reported in the literature. The
aim of this work, therefore, was to further explore the scope of using
two mixed energy VMAT techniques for prostate cancer by:
• evaluating the additive effects of photon energy and dose weight-
ing in Part 1 through dosimetric comparisons of MEPAs (6/
15 MV 1:2 weighted) plans with 6 MV single-arc (6 MV-SA) plans
and 15 MV single-arc (15 MV-SA) plans.
• investigating the sole effect of photon beam energy in Part 2
through dosimetric comparisons of an equal dose weighted MEPAs
(6/15 MV 1:1 weighted), with 6 MV only partial arcs, (6 MV-PA)
plans, and 15 MV only partial arcs (15 MV-PA plans) plans.
2 | MATERIALS AND METHODS
2.A | Patient selection
A cohort of 25 patients with intermediate risk of prostate cancer
who underwent radiation therapy was randomly selected for Part 1
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of this study. A subset of 15 patients was randomly selected for the
Part 2 of this study. For both studies, mean and standard deviation
of planning measurements such as anterior‐posterior separation, lat-
eral separation, planning target volume (PTV), bladder, rectum, and
femoral head volumes are summarized in Table 1. Figure 1 illustrates
the steps taken in generating MEPAs plans and their comparisons
with single energy plans in each part of the study.
2.B | CT simulation and contouring
Computed tomography (CT) scanning and simulations were per-
formed using Philips Brilliance Big Bore Scanner (Philips Medical,
Cambridge, MA) with patients in a supine position and by following
the standard CT scan protocol. The thickness of each CT image in
axial dimension was 1.5 mm. The contouring of prostate, left femur,
right femur, bladder, and rectum was performed by a radiation
oncologist on the axial slices of the CT using the Varian Eclipse™
treatment planning system version 13.7 (Varian Medical Systems,
Palo Alto, CA). The OARs included bladder, rectum, left, and right
femur. The OAR volumes were contoured according to the radiation
therapy oncology group (RTOG‐0815) protocol.16 The prostate was
deﬁned as a clinical target volume from which the PTV was gener-
ated by adding a 5 mm margin in all directions. Mean PTV volume
was 86 ± 25 cc.
2.C | Treatment planning and optimization
In both parts of this study, the total prescription dose (PD) was
79.2 Gy in 44 fractions, with a daily dose of 180 cGy. The goal of
treatment plan was to cover 95% of the PTV volume by at‐least
95% of the PD with no more than 2% of the PTV receiving 107%.
The dosimetric constraints were originally derived based on the
quantitative analysis of normal tissue effects (QUANTEC) require-
ment for prostate cancer.17 For OARs, the goal was to meet the clin-
ically acceptable dose‐volume requirements as shown in Table 2.
2.C.1. | Treatment Plans
For each of the 25 patients in the Part 1 of the study, three volu-
metric modulated arc plans were generated using the RapidArc™
module in Eclipse™: (a) 6 MV plan using a SA, (b) 15 MV plan using
a SA, (c) composite plan using 6 MV anterior–posterior partial arcs,
and 15 MV lateral arcs weighted 1:2 called MEPAs (6/15 MV 1:2
weighted).
The dosimetric outcome of MEPAs (6/15 MV 1:2 weighted) plans
in part 1 of this study may result from additive effects of unequal
dose weighting and the energy. Furthermore, RapidArc™ TPS for
VMAT is an aperture/control point based optimization algorithm,
which may act slightly different for single‐energy single‐arc vs single‐
energy partial arcs. Therefore, to eliminate this effect in addition to
unequal dose weighting, in Part 2, we performed another study with
15 patients in which MEPAs plans weighted 1:1 called MEPAs (6/
15 MV 1:1 weighted) were compared with the 6 MV only partial
arcs plans (6 MV‐PA) and 15 MV only partial arcs (15 MV‐PA) plans.
Thus, the Part 2 of this study would essentially evaluate the inﬂu-
ence of photon beam energy only.
2.C.2. | Gantry and collimator settings
In Part 1 of this study, the gantry angle was set to rotate clockwise
from 181° to 179° for 6 MV‐SA and 15 MV‐SA plans. For MEPAs
(6/15 MV 1:2 weighted), the arc start and stop angles for a 6 MV
were 181°–225°, 315°–45°, and 135°–179° rotating clockwise,
whereas for a 15 MV plan were 225°–315° and 45°–135° rotating
clockwise (Fig. 2).
In Part 2, the arc arrangement for MEPAs (6/15 MV 1:1
weighted), 6 MV‐PA (6 MV as anterior–posterior arcs and 6 MV as
lateral arcs) and 15 MV‐PA (15 MV as anterior–posterior arcs and
15 MV as lateral arcs) were same as the one for MEPAs (6/15 MV
1:2 weighted).
In both parts, the collimator angle was set to 90° for all plans as
it is considered to be a good choice for better OARs sparing in pros-
tate cancer VMAT.18 The isocenter was placed at the center of mass
of the PTV for all the plans.
2.C.3. | Optimization parameters
In Part 1 of this study, two separate single‐energy single‐arc (a
6 MV‐SA plan and a 15 MV‐SA) plans were generated by setting the
optimization objectives, dose volume constraints and priority weight-
ing factors as illustrated in (Table 3). For MEPAs, the following steps
were followed:




First part Second part
MEPAs(6/15 MV 1:2








Sample size 25 15
Age (yr) 67 ± 10 71 ± 9
A‐P separation
(cm)
23 ± 3 24 ± 3
Lateral separation
(cm)
39 ± 6 40 ± 5
PTV volume (cc) 86 ± 25 85 ± 18
Bladder volume
(cc)
251 ± 115 229 ± 96
Rectum
volume (cc)
74 ± 34 81 ± 36
Right femur
volume (cc)
182 ± 20 188 ± 21
Left femur
volume (cc)
181 ± 21 187 ± 23
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1. A 6 MV anterior and posterior partial arcs plan was created by
setting the optimization objectives, constraints, and weightings as
shown in (Table 3). The 6 MV partial arcs plan delivered 26.4 Gy
over 44 fractions.
2. A 15 MV lateral arcs plan was then generated by setting the
optimization objectives, constraints, and weightings as shown in
(Table 3). Since Eclipse does not allow mixing energies in Rapi-
dArc™ module, the 15 MV lateral arcs plan was optimized by
using the 6 MV anterior-posterior arcs plan as a base plan. The
15 MV lateral arcs plan delivered 52.8 Gy over 44 fractions.
3. As a ﬁnal step, plans from the previous steps, 6 MV anterior-pos-
terior arcs plan and 15 MV lateral arcs plan were summated to
generate a MEPAs (6/15 MV 1:2 weighted) plan.
In the Part 2 of this study, 6 MV only partial arcs plans (6 MV‐
PA), 15 MV only partial arcs plans (15 MV‐PA), and MEPAs plans
weighted 1:1, MEPAs (6/15 MV 1:1 weighted), were generated by
using optimization parameters shown in Table 4. MEPAs (6/15 MV
1:1 weighted) plans were generated by following the aforementioned
steps 2 and 3, but with an equal dose weighting.
In both parts of this study, the beam arrangement (6 MV ante-
rior–posterior arcs and 15 MV lateral arcs) was selected based on
the anatomical location of the target and surrounding OARs, and
required photon beam penetrating power. The beam parameters,
optimization objectives, dose‐volume constraints, and weighting fac-
tors were kept constant for the 25 patients studied in Part 1 and for
the 15 patients studied in Part 2.
To avoid hot spots in the normal tissue, normal tissue objective
(NTO) feature of Eclipse™ TPS was used with the priority of 100 in
Study Design for Part 1
6MV – PA (1/3 dose weighted)
plan optimization
15MV – PA (2/3 dose weighted) 
plan optimization 
Here, 6MV-PA 1/3 dose weighted 
plan was set as a base plan
Summation (6MV-PA + 15MV-PA)
MEPAs (6/15MV 1:2 weighted)
Plan 
Comparisons 
6MV – SA 15MV – SA
Study Design for Part 2
6MV – PA (1/2 dose weighted) 
plan optimization
15MV – PA (1/2 dose weighted)
plan optimization 
Here, 6MV-PA 1/2 dose weighted 
plan was set as a base plan
Summation (6MV-PA + 15MV-PA)
MEPAs (6/15MV 1:1 weighted)
6MV – PA 15MV – PA
Plan 
Comparisons
F I G 1 . Flow charts illustrating the steps
taken in generating mixed energy partial
arcs plans and their comparisons with
single energy plans in Part 1 (left) and Part
2 (right) of this study.
TA B L E 2 The QUANTEC based dose‐volume restrictions for OARs
including femoral heads, rectum, and bladder.
Femoral
heads V50 < 5%
Rectum V75 < 15%, V70 < 20%,
V65 < 25%, V60 < 35%, V50 < 50%
Bladder V80 < 15%, V75 < 25%,
V70 < 35%, V65 < 50% Dmax < 65 Gy
Femoral heads V50 < 5% represents no more than 5% of either femoral
heads should receive a dose of 50 Gy or more. Dmax = Maximum Dose.
F I G 2 . Arc start and stop angles for a Volumetric Arc Therapy
(VMAT) mixed energy partial arcs plan using partial arcs in Eclipse
treatment planning system.
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combination with the falloff value of 0.05 cm−1. The NTO distance
from the target border, start dose, and end dose were 1 cm, 105%,
and 60%, respectively. No normalization was required in both studies
to achieve dosimetric goals of the treatment.
2.D | Dosimetric parameters
The dose volume histograms (DVH) were generated for each plan in
Eclipse for dosimetric evaluation and comparison. The dose calcula-
tion was performed with the anisotropic analytical algorithm (AAA
— Version 13.7.16) with a 2.5 mm calculation grid. PTV coverage











where TVT,ref. represents the volume of the target volume covered by
the 95% of the isodose, Vref represents the total volume receiving 95%
of the isodose (Vref was determined by converting isodose to structure
feature in Eclipse), VT represents PTV volume. This conformity assess-
ment in Eq. (1) accounts for both target coverage (the ﬁrst brackets)
and the proximity of isodose line to the target (the second brackets). A
CN value closer to 1 is considered a perfectly conformal plan.
Similarly, the mean and maximum dose, and hotspot determined
by D2% (dose received by 2% of PTV) were recorded for each case.
To evaluate the dose homogeneity within the PTV, the homogeneity
index (HI) was deﬁned as per ICRU83 by taking a ratio of difference
of D2% (dose delivered to 2% of the PTV) and D98% (dose delivered
to 98% of the PTV), and dose delivered to 50% of the PTV.21 The





For OARs, the volumes receiving 70, 50, 30, and 20 Gy (V70Gy,
V50Gy, V30Gy, and V20Gy) were calculated to evaluate various irradi-
ated volumes of bladder and rectum. The mean dose was calculated
to evaluate dose to femoral heads.
The average differences between 6 MV‐SA and MEPAs, and
between 15 MV‐SA and MEPAs in corresponding dosimetric param-










In Eq. (3), Q represents beam energy that is, 6 or 15 MV, x rep-
resents the dosimetric parameter to be analyzed, and n represents
the total number of patients, 25 for the ﬁrst part, and 15 for the
second part. Since current standards of care use single arc with sin-
gle energy, they were compared to the MEPAs. The 6 MV‐SA plans
and 15 MV‐SA plans were used as standard plans to evaluate the
average difference (Davg) between 6 MV‐SA and MEPAs (6/15 MV
1:2 weighted), and 15 MV‐SA and MEPAs (6/15 MV 1:2 weighted).
This was repeated for the Part 2 in which 6 and 15 MV‐PA plans
were used as standard plans to evaluate the average difference
between 6 MV‐PA and MEPAs (6/15 MV 1:1 weighted), and 15 MV‐
PA and MEPAs (6/15 MV 1:1 weighted).
2.E | Statistical analysis
In Part 1, the dosimetric parameters of MEPAs (6/15 MV 1:2
weighted) plans were statistically compared with the dosimetric
TA B L E 3 Dose volume constraints and priority factors set in
RapidArc™ treatment planning software for optimization of 25
patients in ﬁrst study involving MEPA(6/15 MV 1:2 weighted),
6 MV‐SA and 15 MV‐SA plans.
Structure Vol (%) Dose (% of PD) Priority factor
PTV 0 105% 250
100 101.1% 250








Left femur 0 50% 150
Right femur 0 50% 150
PD: prescribed dose; 6 MV‐SA: 79.2 Gy (PD); 15 MV‐SA: 79.2 Gy (PD);
6 MV‐partial arcs: 26.4 Gy (PD); 15 MV‐partial arcs: 79.2 Gy (PD); PTV:
planning target volume.
TA B L E 4 Dose volume constraints and priority factors set in
RapidArc™ treatment planning software for optimization of 15
patients in second study involving MEPA(6/15 MV 1:1 weighted), 6
and 15 MV‐PA plans.
Structure Vol (%) Dose (% of PD) Priority factor
PTV 0 105% 250
100 101.1% 250








Left femur 0 50% 35
Right femur 0 50% 35
PD: Prescribed dose; 6 MV‐PA: 79.2 Gy (PD); 15 MV‐PA: 79.2 Gy (PD);
6 MV‐partial arcs: 39.6 Gy (PD); 15 MV‐partial arcs: 79.2 Gy (PD); PTV:
planning target volume.
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parameters of 6 and 15 MV‐SA using a two‐tailed paired‐sample t‐test.
In addition, the 95% conﬁdence interval is included for each P‐value.
In Part 2, the dosimetric parameters of MEPAs (6/15 MV 1:1
weighted) plans were statistically compared with the dosimetric param-
eters of 6 and 15 MV‐PA using a two‐tailed paired‐sample t‐test.
At this point, it is important to note that both parts of this study
are independent of each other and no cross comparison was done
between dosimetric parameters of the two parts. Statistical analysis
was conducted by using IBM SPSS Statistics 24 (IBM Corp. Released
2017. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY:
IBM Corp). For both studies, a P < 0.05 was considered to be statis-
tically signiﬁcant. Prior to two‐tailed t‐test, the data were checked
for normal distribution by performing the Shapiro–Wilk test.22
3 | RESULTS
3.A | Part 1
3.A.1 | Dosimetry
The dosimetric parameters averaged over 25 cases for the 6 MV‐SA,
15 MV‐SA, and MEPAs (6/15 MV 1:2 weighted) is highlighted in
Table 5. The statistical differences between 6 MV‐SA and MEPAs (6/
15 MV 1:2 weighted), and 15MV‐SA and MEPAs (6/15 MV 1:2
weighted) plans are shown in Table 6. The average differences,
D6MVavg andD
15MV
avg , for dosimetric parameters of the PTV, bladder, rec-
tum, and as well as number of Monitor Units (MU), CI, and HI are
shown in Table 7.
3.A.2 | Doses to the PTV
Mixed energy partial arcs (6/15 MV 1:2 weighted) resulted in a lower
maximum dose to the PTV in comparison to 6 MV‐SA (P < 0.0005)
and 15 MV‐SA (P < 0.0005). (Table 5). Mean doses to the PTV of
MEPAs (6/15 MV 1:2 weighted) plans was comparable to 15 MV‐SA
plans (P = 0.06), but higher compared to 6 MV‐SA (P = 0.01) plans
(Tables 5 and 6). The D2% of the PTV of MEPAs (6/15 MV 1:2
weighted) plans was comparable to both 6 MV‐SA (P = 0.67) and
15 MV‐SA (P = 0.87) plans (Table 6).
In comparison to 6 and 15 MV‐SA plans, MEPAs (6/15 MV 1:2
weighted) produced statistically equivalent conformity number
(P = 0.1), however, it resulted in slightly inferior target homogeneity
index (P < 0.0005) (Table 6). A negative average differ-
enceD6MVavg andD
15MV
avg , indicated higher values for HI of MEPAs (6/
15MV 1:2 weighted) plans (Table 7).
3.A.3 | Doses to the bladder
As indicated by positive values of D6MVavg andD
15MV
avg in Table 7, the
dosimetric parameters for bladder were always lower for MEPAs (6/
15 MV 1:2 weighted) plans compared to 6 and 15 MV‐SA plans
(Tables 5 and 7). MEPAs (6/15 MV 1:2 weighted) irradiated signiﬁ-
cantly lower volume than 6 and 15 MV‐SA, with an exception of
V70Gy (P = 0.08) and V50Gy (P = 0.09) for 6 MV‐ SA (Tables 6 and 7).
TA B L E 5 The dosimetric parameters for 6 MV‐SA, 15 MV‐SA, and
MEPAs (6/15 MV 1:2 weighted) plans. The data are averaged over










PTV Max dose (Gy) 87.1 ± 1.2 86.6 ± 1.3 86.0 ± 1.2
95% CI (Gy) 86.6–87.6 86.0–87.1 85.2–86.7
Mean dose (Gy) 81.1 ± 0.4 81.3 ± 0.6 81.2 ± 0.4
95% CI (Gy) 80.9–81.3 81.1–81.6 81.0–81.4
D2% (Gy) 83.9 ± 0.6 84.0 ± 0.7 84.0 ± 0.6
95% CI (Gy) 86.7–84.2 83.7–84.3 83.7–84.3
HI 0.08 ± 0.02 0.08 ± 0.02 0.09 ± 0.02
95% CI 0.08–0.09 0.08–0.09 0.09–0.1
CN 0.82 ± 0.04 0.82 ± 0.04 0.83 ± 0.05
95% CI 0.80–0.83 0.80–0.84 0.80–0.84
Bladder Max dose (Gy) 85.9 ± 1.7 85.5 ± 1.6 84.6 ± 1.2
95% CI (Gy) 85.3–86.6 84.9–86.3 84.1–85.1
Mean dose (Gy) 14.2 ± 6.6 14.1 ± 6.8 13.6 ± 6.1
95% CI (Gy) 11.5–16.9 11.3–16.9 10.8–15.8
V70Gy (%) 4.2 ± 2.0 4.2 ± 2.0 4.1 ± 2.1
95% CI (%) 3.4–5.0 3.4–5.0 3.2–4.9
V50Gy (%) 8.9 ± 4.1 9.1 ± 4.4 8.5 ± 4.2
95% CI (%) 7.2–10.6 7.2–10.9 6.8–10.3
V30Gy (%) 17.4 ± 9.7 17.6 ± 9.9 15.7 ± 8.8
95% CI (%) 13.3–21.4 13.5–21.7 12.1–19.3
V20Gy (%) 22.9 ± 13.9 23.7 ± 13.8 21.2 ± 12.0
95% CI (%) 17.1–28.6 18.0–29.3 16.2–26.1
Rectum Max dose (Gy) 85.0 ± 1.7 84.8 ± 1.4 84.1 ± 1.4
95% CI (Gy) 84.3–85.7 84.3–85.4 83.5–84.6
Mean dose (Gy) 25.3 ± 3.4 25.7 ± 3.8 23.0 ± 3.6
95% CI (Gy) 23.9–26.7 24.1–27.3 21.5–24.5
V70Gy (%) 6.6 ± 2.1 6.7 ± 2.1 7.1 ± 2.1
95% CI (%) 5.7–7.4 5.8–7.5 6.2–7.9
V50Gy (%) 15.2 ± 2.9 16.3 ± 3.5 15.8 ± 3.8
95% CI (%) 14.0–16.4 14.8–17.7 14.3–17.4
V30Gy (%) 40.1 ± 5.8 40.1 ± 7.1 31.4 ± 6.8
95% CI (%) 37.7–42.5 37.5–43.3 28.6–34.2
V20Gy (%) 52.2 ± 8.0 53.2 ± 8.6 42.4 ± 7.2
95% CI (%) 48.9–55.5 49.6–56.7 39.4–45.4
L femur Mean dose (Gy) 11.1 ± 2.2 11.0 ± 2.2 14.9 ± 3.1
95% CI (Gy) 10.2–12.0 10.1–12.0 13.6–16.2
Max dose (Gy) 30.7 ± 5.6 30.0 ± 5.2 39.6 ± 4.7
95% CI (Gy) 28.5–32.9 28.0–32.0 37.7–41.4
R femur Mean dose (Gy) 10.9 ± 2.9 11.0 ± 2.3 15.3 ± 2.9
95% CI (Gy) 9.8–12.2 10.0–12.1 14.1–16.5
Max dose (Gy) 30.9 ± 5.4 30.6 ± 5.6 40.5 ± 3.5
95% CI (Gy) 28.8–33.0 28.4–32.8 39.2–41.9
MUs 637 ± 84 514 ± 50 435 ± 104
95% CI (MUs) 602–673 493–535 398–474
MEPAs: mixed energy partial arcs; SA: single arc; PTV: planning target
volume; SD: standard deviation.
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This can also be observed in 95% CI for each P‐value, which
excludes the null value, zero, for signiﬁcance and includes the null
value, zero, for insigniﬁcance. Furthermore, the maximum dose to
bladder exceeded 65 Gy for all three techniques without signiﬁcant
difference among three techniques. (Tables 5 and 6).
3.A.4 | Doses to the rectum
The mean dose to the rectum was ~2 Gy lower for MEPAs (6/
15 MV 1:2 weighted) plans compared to 6 MV‐SA (P < 0.0005) and
15 MV‐SA (P < 0.0005) plans (Tables 5 and 6) with a positive aver-
age difference D6MVavg andD
15MV
avg of 9 ± 8% and 10 ± 8% (Table 7).
MEPAs (6/15 MV 1:2 weighted) plans covered signiﬁcantly lower
volume of rectum at V30Gy and V20Gy dose levels compared to
6 MV‐SA (P < 0.0005), and 15 MV‐SA (P < 0.0005), but not at sta-
tistical signiﬁcance threshold for V50Gy (Tables 5 and 6).
3.A.5 | Doses to the femoral heads
MEPAs (6/15 MV 1:2 weighted) resulted in an increased mean doses
and maximum doses to both femoral heads by ~4.0 and ~10.0 Gy
compared to 6 MV‐SA (P < 0.0005) and 15 MV‐SA (P < 0.0005;
Tables 5 and 6). This difference can be observed by negative values
of D6MVavg andD
15MV
avg in (Table 7).
3.A.6 | Monitor units
The number of MUs was lower for MEPAs (6/15 MV 1:2 weighted)
plans by 202 and 79 MU compared to 6 MV‐SA (P < 0.0005) and
15 MV‐SA (P < 0.0005), respectively, (Tables 5 and 6).
3.A.7 | Dose distribution
The dose distributions in color‐wash view resulting from RapidArc™
planning with 6 MV‐SA, 15 MV‐SA, and MEPAs (6/15 MV 1:2
weighted) for one representative case in transverse plane is demon-
strated in Fig. 3. MEPAs (6/15 MV 1:2 weighted) technique pro-
duced tighter dose distribution in anterior‐posterior direction, where
bladder and rectum are close to the PTV, but produced wider dose
spread in lateral direction compared to 6 and 15 MV‐SA (Figure 3).
The DVHs for all three, a 6 MV‐SA, a 15 MV‐SA, and a MEPAs (6/
15 MV 1:2 weighted), plans are shown in Fig. 4, which shows large
differences in the volumetric doses to rectum and femoral heads
among three techniques.
TA B L E 6 Statistical comparison of dosimetric parameters between (a) 6 MV‐SA and MEPAs (6/15 MV 1:2 weighted) and (b) 15 MV‐SA and
MEPAs (6/15 MV 1:2 weighted). The dosimetric parameters are averaged over the cohort of 25 patients.
Structure Dosimetric parameter
6MV‐SA vs MEPAs (1:2 weighted) 15MV‐SA vs MEPAs (1:2 weighted)
P‐value 95% CI P‐value 95% CI
PTV Max dose (Gy) <0.0005 0.70, 1.59 0.03 0.07, 1.23
Mean dose (Gy) 0.01 −0.24, −0.03 0.06 −0.01, 0.24
D2% (Gy) 0.67 −0.26, 0.17 0.87 −0.18, 0.21
HI <0.0005 −0.02, −0.01 <0.0005 −0.02, −0.005
CN 0.1 −0.02, 0.002 0.1 −0.02, 0.003
Bladder Max dose (Gy) 0.01 0.67, 2.00 <0.0005 0.21, 1.66
Mean dose (Gy) <0.0005 0.49, 1.41 <0.0005 0.36, 1.36
V70Gy (%) 0.08 −0.02, 0.27 0.04 0.01, 0.27
V50Gy (%) 0.09 −0.06, 0.74 0.02 0.10, 0.97
V30Gy (%) 0.002 0.70, 2.65 <0.0005 1.01, 4.34
V20Gy (%) 0.02 0.21, 3.27 0.001 1.11, 3.87
Rectum Max dose (Gy) 0.001 0.42, 1.44 0.002 0.31, 1.18
Mean dose (Gy) <0.0005 1.41, 3.08 <0.0005 1.74, 5.98
V70Gy (%) 0.005 −0.88, −0.18 0.01 −0.75, −0.10
V50Gy (%) 0.22 −1.61, 0.38 0.39 −0.62, 1.54
V30Gy (%) <0.0005 6.52, 10.84 <0.0005 6.26, 11.7
V20Gy (%) <0.0005 6.84, 12.72 <0.0005 7.72, 13.79
Left femur Mean dose (Gy) <0.0005 −4.77, ‐2.79 <0.0005 −4.94, −2.78
Max dose (Gy) <0.0005 −11.02, −6.78 <0.0005 −11.96, −7.19
Right femur Mean dose (Gy) <0.0005 −5.53, −3.04 <0.0005 −5.43, −3.04
Max dose (Gy) <0.0005 −11.53, −7.72 <0.0005 −11.83, −8.00
MUs <0.0005 163.4, 239.6 <0.0005 43.14, 113.3
MEPAs: mixed energy partial arcs; SA: single arc; MUs: monitor units; Avg: average; PTV: planning target volume; SD: standard deviation; P ≤ 0.0005
represents a P value of 0.
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3.B | Part 2
In this part of the study, MEPAs (6/15 MV 1:1 weighted) plans were
compared with 6 MV only partial arcs (6 MV‐PA) and 15 MV only
partial arcs (15 MV‐PA) for a cohort of 15 patients to evaluate the
inﬂuence of photon beam energy only.
3.B.1 | Doses to the PTV
No statistically signiﬁcant differences were observed between
MEPAs (6/15 MV 1:1 weighted) and 6 MV‐PA, and MEPAs (6/
15 MV 1:1 weighted) and 15 MV‐PA for maximum doses to the
PTV (Table 9). The mean doses to the PTV were statistically lower
for MEPAs (6/15 MV 1:1 weighted) plans compared to 15 MV‐PA
plans (P < 0.0005; Tables 8 and 9), but no statistical signiﬁcance
was reached for mean doses to the PTV for comparison between
MEPAs (6/15 MV 1:1 weighted) plans and 6 MV‐PA plans
(Table 9).
MEPAs (6/15 MV 1:1 weighted) plans signiﬁcantly improved the
dose conformity to the PTV compared to 6 MV‐PA (0.83 vs 0.77;
P < 0.0005) plans and 15 MV‐PA (0.83 vs 0.78; P < 0.0005) plans
(Table 9). This can also be observed by negative average differences,
D6MVavg andD
15MV
avg , in Table 10. However, MEPAs (6/15 MV 1:1
weighted) plans produced inferior target homogeneity compared to
6 MV‐PA plans (0.06 vs 0.07; P = 0.01) (Table 9).
3.B.2 | Doses to the Bladder
All the dosimetric parameters, except maximum dose to bladder,
were statistically lower for MEPAs (6/15 MV 1:1 weighted) plans
compared to 6 and 15 MV‐PA plans (Table 8 and 9). This difference
can also be observed in Table 10 by positive values of average dif-
ference, D6MVavg and D
15MV
avg , for both comparisons.
3.B.3 | Doses to the rectum
Mean dose to the rectum for MEPAs (6/15 MV 1:1 weighted) plans
was ~4 Gy lower than 6 MV‐PA (P < 0.0005) and 15 MV‐PA plans
(P < 0.0005; Tables 8 and 9). Furthermore, MEPAs (6/15 MV 1:1
weighted) covered signiﬁcantly lower amount of rectal volume at all
TA B L E 7 The average difference, Davg (%), of dosimetric parameters between 6 MV‐SA and MEPAs (6/15 MV 1:2 weighted), and between
15 MV‐SA and MEPAs (6/15 MV 1:2 weighted)
Structure Dosimetric parameter
Avgdiff ± SD.
6 MV‐SA vs MEPAs ðD6MVAvg Þ
Avgdiff. ± SD
15 MV‐SA vs MEPAs ðD15MVAvg Þ
PTV Min dose (%) 0 ± 4.0 1.0 ± 3.59
Max dose (%) 0.7 ± 3.3 0.9 ± 1.84
Mean dose (%) ‐0.9 ± 3.6 0.3 ± 0.99
HI (%) −22.4 ± 24.4 −19.0 ± 25.7
CN (%) −1.3 ± 3.5 −1.1 ± 3.5
Bladder Max dose (%) 1.6 ± 1.9 1.1 ± 2.0
Mean dose (%) 6.2 ± 7.0 4.7 ± 7.1
V70Gy (%) 5.8 ± 13.7 5.7 ± 11.1
V50Gy (%) 5.3 ± 14.7 6.5 ± 13.0
V30Gy (%) 8.7 ± 13.2 10.2 ± 12.0
V20Gy (%) 5.3 ± 11.8 9.3 ± 10.7
Rectum Max dose (%) 1.1 ± 1.4 0.9 ± 1.2
Mean dose (%) 8.8 ± 7.7 10.1 ± 8.2
V70Gy (%) −9.3 ± 17.1 −7.5 ± 14.6
V50Gy (%) −4.0 ± 17.1 2.5 ± 15.7
V30Gy (%) 21.7 ± 12.9 21.6 ± 14.1
V20Gy (%) 18.2 ± 11.5 19.5 ± 11.4
L Femur Mean dose (%) −35.5 ± 23.1 −37.4 ± 26.5
Max dose (%) −31.9 ± 21.7 −34.6 ± 21.8
R Femur Mean dose (%) −90.6 ± 277.0 −46.4 ± 24.7
Max dose (%) −34.2 ± 21.4 −35.4 ± 20.6
MUs 29.8 ± 19.7 12.9 ± 26.6




Avg were calculated using Eq. (3). PTV: plan-
ning target volume
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F I G 3 . The dose distribution of a 6 MV‐
SA, a 15 MV‐SA, and a MEPAs (6/15 MV
1:2 weighted) plan with an equal dose
weight for one representative case in
transversal views.
F I G 4 . Dose volume histograms for 6 MV‐SA (Circles), 15 MV‐SA (Triangles), and MEPAs (6/15 MV 1:2 weighted) (Squares) for PTV in
yellow, rectum in brown, right femur in blue, left femur in pink, and bladder in clover‐lime.
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dose levels (V70Gy = 9%, V60Gy = 14%, V45Gy = 26% and V15Gy =
57%) compared to 6 MV‐PA (V70Gy = 12%, V60Gy = 20%, V45Gy =
33% and V15Gy = 59%) and 15MV‐PA (V70Gy = 12%, V60Gy = 19%,
V45Gy = 32% and V15Gy = 60%; Tables 8 and 9).
3.B.4 | Doses to the femoral heads
MEPAs (6/15 MV 1:1 weighted) resulted in increased mean doses to
right femur (P = 0.04) and left femur (P = 0.048) compared to
TA B L E 8 The dosimetric parameters for 6 MV‐PA, 15 MV‐PA, and MEPAs (6/15 MV 1:1 weighted). The dosimetric parameters are averaged








PTV Max dose (Gy) 86.7 ± 0.9 86.0 ± 0.5 86.4 ± 1.2
95% CI (Gy) 86.3–87.3 86.7–86.3 85.8–87.1
Mean dose (Gy) 81.7 ± 0.4 82.1 ± 0.5 81.6 ± 0.3
95% CI (Gy) 81.4–81.9 81.8–82.4 81.4–81.8
D2% (Gy) 84.0 ± 0.4 84.2 ± 0.5 83.7 ± 0.4
95% CI (Gy) 83.8–84.2 83.9–84.5 83.5–84.0
HI 0.06 ± 0.01 0.07 ± 0.01 0.07 ± 0.1
95% CI 0.06–0.07 0.06–0.07 0.07–0.08
CN 0.77 ± 0.05 0.78 ± 0.05 0.83 ± 0.03
95% CI 0.75–0.80 0.75–0.81 0.81–0.84
Bladder Max dose (Gy) 85.7 ± 1.1 85.6 ± 1.1 85.6 ± 1.6
95% CI (Gy) 85.1–86.3 85.0–86.3 84.9–86.6
Mean dose (Gy) 17.5 ± 8.1 17.7 ± 7.8 15.2 ± 7.6
95% CI (Gy) 13.0–22.0 13.0–22.0 11.0–19.4
V70Gy (%) 5.0 ± 2.8 4.9 ± 2.6 4.2 ± 2.4
95% CI (%) 3.4–6.5 3.5–6.4 2.9–5.6
V60Gy (%) 7.8 ± 4.2 7.7 ± 4.1 6.7 ± 3.7
95% CI (%) 5.4–10.1 5.6–10.1 4.7–8.8
V45Gy (%) 13.2 ± 8.5 13.3 ± 7.9 11.1 ± 6.8
95% CI (%) 8.5–17.9 8.9–17.7 7.3–14.9
V15Gy (%) 32.1 ± 19.9 33.9 ± 19.6 29.3 ± 19.2
95% CI (%) 21.02–43.1 23.0–44.8 18.6–40.0
Rectum Max dose (Gy) 85.2 ± 1.4 84.9 ± 1.1 84.7 ± 1.5
95% CI (Gy) 84.4–86.0 84.3–85.5 83.9–85.6
Mean dose (Gy) 31.7 ± 4.4 32.4 ± 4.2 27.2 ± 4.8
95% CI (Gy) 29.4–34.2 30.1–34.7 24.6–30.0
V70Gy (%) 12.3 ± 5.9 11.7 ± 5.4 8.5 ± 3.6
95% CI (%) 9.0–15.6 8.7–14.7 6.5–10.5
V60Gy (%) 19.9 ± 8.4 19.4 ± 7.9 13.8 ± 4.2
95% CI (%) 15.2–24.6 15.1–23.8 11.5–16.2
V45Gy (%) 33.4 ± 9.9 32.3 ± 8.7 26.2 ± 5.1
95% CI (%) 28.0–38.9 28.2–37.8 23.4–29.1
V15Gy (%) 59.3 ± 10.8 60.4 ± 11.2 56.7 ± 11.3
95% CI (%) 53.3–65.3 54.2–66.6 50.5–63.0
Left femur Mean dose (Gy) 10.3 ± 2.9 10.1 ± 3.0 12.0 ± 2.7
95% CI (Gy) 8.8–11.9 8.4–11.8 10.6–13.5
Right femur Mean dose (Gy) 10.3 ± 2.4 10.0 ± 2.8 12.3 ± 2.9
95% CI (Gy) 8.9–11.6 8.5–11.5 10.7–13.9
MUs 553 ± 88 442 ± 57 480 ± 73
95% CI (MUs) 504–602 411–474 440–521
MEPAs: mixed energy partial arcs; PA: partial arc; PTV: planning target volume SD: standard deviation.
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15 MV‐PA (Table 8 and 9). There is a noticeable difference in mean
doses to femoral heads of MEPAs (6/15 MV 1:1 weighted) plans and
6 MV‐PA plans (Table 8), but no statistical signiﬁcance was observed
(P = 0.12 and P = 0.05 for left and right femur, respectively;
Table 9).
3.B.5 | Monitor units
The total number of monitor units for MEPAs (6/15 MV 1:1
weighted) plans was higher than that of 15 MV‐PA plans (480 vs
442 MUs; P = 0.04; Tables 8 and 9) with an average negative differ-
ence of 9% (Table 10), but lower than that of 6 MV‐PA plans (480
vs 553 MUs; P < 0.0005; Tables 8 and 9) with an average positive
difference of 13% (Table 10).
3.B.6 | Dose distribution
Figure 5 shows the dose distributions in color‐wash view for 6 MV‐
PA, 15 MV‐PA, and MEPAs (6/15 MV 1:1 weighted) plans for one
representative case along sagittal views. MEPAs (6/15 MV 1:1
weighted) plans appear to produce a tighter dose distribution with
the greater avoidance of OARs in comparison to 6 and 15 MV‐PA
plans (Figure 5).
4 | DISCUSSION
Manually choosing multiple photon energies in an IMRT plan is not
practiced very commonly except for a few clinical sites such as
breast. However, for VMAT, only a single energy approach is cur-
rently being used in the clinics, presumably due to lack of sufﬁcient
evidences indicating superiority of using multiple energies over a sin-
gle energy, and complexity arising due to several energies. In this
work, we investigated the dosimetric quality of two MEPAs tech-
niques for prostate cancer VMAT. In Part 1, MEPAs (6/15 MV 1:2
weighted) plans reduced the total number of monitor units, while
sparing OARs and maintaining dose conformity to the PTV compared
to standard 6 MV‐SA or 15 MV‐SA techniques. However, higher
doses to femoral heads and slightly inferior HI of MEPAs (6/15 MV
1:2 weighted) plans should also be noted. Slightly degraded HI could
be due to the optimization parameters including priority weighting
factors, which, in this work, were kept the same to avoid biasing the
results. Greater emphasis on priority weighting factor can essentially
improve the HI. Lower doses to the bladder and rectum, and higher
doses to the femoral heads by MEPAs (6/15 MV 1:2 weighted) plans
were likely to be the result of 6/15 MV 1:2 dose weighting. As a
result, a smaller dose proportion of PD by a lower energy (6 MV)
beam produced tighter dose distribution in anterior and posterior
TA B L E 9 Statistical comparison of dosimetric parameters between (a) 6 MV‐PA and MEPAs (6/15 MV 1:1 weighted) and (b) 15 MV‐PA and




6 MV‐PA vs MEPAs (1:1 weighted) 15 MV‐PA vs MEPAs (1:1 weighted)
P‐value 95% CI P‐value 95% CI
PTV Max dose (Gy) 0.34 −4.40, 1.19 0.16 −1.12, 0.21
Mean dose (Gy) 0.13 −0.04, 0.25 <0.0005 0.11, 0.3
D2% (Gy) 0.02 0.05, 0.50 0.002 0.21, 0.77
HI 0.01 −0.01, −0.003 0.05 −0.006, −0.03
CN <0.0005 −0.07, −0.03 <0.0005 −0.008, 0.002
Bladder Max dose (Gy) 0.88 −0.63, 1.52 0.99 −0.64, 0.87
Mean dose (Gy) <0.0005 2.1, 5.93 <0.0005 2.72, 6.59
V70Gy (%) 0.001 0.34, 1.06 <0.0005 0.44, 0.89
V60Gy (%) 0.001 0.51, 1.62 <0.0005 0.67, 1.63
V45Gy (%) 0.007 0.67, 3.57 0.001 1.16, 3.28
V15Gy (%) 0.001 1.34, 4.42 0.001 2.27, 6.86
Rectum Max dose (Gy) 0.75 −0.56, 0.65 0.39 −0.87, 0.86
Mean dose (Gy) <0.0005 1.37, 3.1 <0.0005 1.53, 2.92
V70Gy (%) 0.001 1.93, 5.7 0.001 1.62, 4.71
V60Gy (%) 0.001 2.96, 9.19 0.001 1.29, 2.81
V45Gy (%) 0.007 2.37, 12.06 0.003 2.77, 10.74
V15Gy (%) 0.01 1.29, 3.92 <0.0005 2.41, 5.01
Left femur Mean dose (Gy) 0.12 −3.83, 0.46 0.048 −3.8, −0.01
Right femur Mean dose (Gy) 0.05 −3.98, 0.01 0.04 −4.36, −0.18
MUs <0.0005 44, 100 0.04 −74, −2
MEPAs: mixed energy partial arcs; SA: single arc; MUs: monitor units; Avg: average; PTV: planning target volume; SD: standard deviation; P ≤ 0.0005
represents a P value of 0.
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regions of the PTV and a greater dose proportion of PD by a higher
energy (15 MV) beam produced greater dose spread in the lateral
direction (Figure 3). All three plans (MEPAs [6/15 MV 1:2 weighted],
6 and 15 MV‐SA) met the QUANTEC criteria, except maximum dose
to bladder, due to not including the maximum dose constraint during
optimization.
With an exception of degraded HI and lower MUs, the results of
Part 1 of this study are in agreement with a previous study,14 which
compared dosimetric quality of single‐energy partial‐arc (30°–165°
and 195°–330°) VMAT plans with that of a single‐energy full‐arc
(0°–359°) VMAT plans for prostate and demonstrated that partial
arcs technique results in lower doses to the bladder and rectum but
at an expense of higher doses to femoral heads.14 Our results, how-
ever, cannot be directly compared against the previous studies, as to
our knowledge, MEPA VMAT technique has not been reported pre-
viously. A study comparing single‐arc vs dual arcs VMAT for prostate
cancer demonstrated superior OARs sparing using dual arcs tech-
nique,23 whereas another study suggested single‐arc technique to be
superior over dual arcs VMAT for OARs sparing.17
In Part 2 of this study, we investigated the sole effects of energy
by comparing MEPAs (6/15 MV 1:1 weighted) with 6 and 15
MV‐PA with the same arc lengths and optimization parameters, by
eliminating the heuristic weighting scheme. This study showed that
MEPAs (6/15 MV 1:1 weighted) improved CN, reduced doses to
bladder and rectum by covering lower volume of OARs at all dose
levels, and lowered MUs, but increased doses to the femoral heads
compared to 6 and 15 MV‐PA. The results of Part 2 of this study
are in agreement with the only previous study on mixed energy
VMAT technique,24 which compared dual arcs mixed energy VMAT
plans (one energy per one arc) with a single‐energy dual arcs plans
for prostate cases involving seminal vesicles and lymph nodes. Our
study involved comparison of a full arc split into MEPAs, MEPAs (6/
15 MV 1:1 weighted), with a single‐energy partial‐arc plans (6 and
15 MV‐PA) for prostate only. Furthermore, for prostate cancer
patients with AP separation greater than 21 cm, the higher energy
(10 MV) plans were reported to be superior in sparing OARs and
lowering monitor units compared to lower energy (6 MV) plans.25
In assessing clinical importance, it has been previously reported
that rectum volume receiving ≤30 Gy reduced the incidence of sev-
eral types of patient‐reported late rectal toxicities by 10%–18%.26
MEPAs (6/15 MV 1:2 weighted) reduced V30Gy by 9% compared to 6
and 15 MV‐SA (Table 5). The rectum volume receiving ≥60 Gy is
associated with late rectal complication,27 MEPAs (6/15 MV 1:1
weighted) technique reduced V60Gy by 6% compared to both 6 and
15 MV‐PA techniques (Table 8). It has been reported that late rectal
complications occurred in 3/7 patients and 4/7 patients when a dose
of 70 Gy or more was delivered to at least 7% and 3% of the rectal
volume, respectively.28 It should be noted that the V70Gy ranged from
6% to 7% in Part 1 (Table 5) and 8% to 11% in Part 2 of this study
(Table 8). In comparison to 6 and 15 MV‐SA, possible occurrences of
post‐EBRT rectal complications might be reduced by MEPAs (6/
15 MV 1:2 weighted) as it only delivers 1/3 of the PD with bladder
and rectum being in direct path of the beam. Complications in
femoral heads such as fractures and necrosis can be kept to less than
5% if the mean dose to <50 Gy to limit.29 Though MEPA (6/15MV
1:2 weighted) delivers 2/3 of the PD from lateral arcs, the mean dose
to the femoral heads were well below 20 Gy. According to Cefaro et
al., the likelihood of a fracture of the femoral heads is greater than
5% when maximum dose to the femoral heads exceeds 40–45 Gy.30
The maximum dose deposited to the left and right femur by MEPA
(6/15 MV 1:2 weighted) technique was 38 and 41 Gy, respectively.
This is due to the greater proportion of PD delivered from lateral
direction. In future studies, the potential of MEPAs technique can
further be improved by optimizing the dose weighting factor for each
energy in MEPAs plans. The dose‐volume speciﬁcations for bladder
complications are not as well studied as for rectum. Vargas et al. have
reported that reductions in the low doses area for bladder have been
associated with lower long‐term urinary side effects.31 MEPA (6/
15 MV 1:2 weighted) reduced the volume covered by 20 and 30 Gy
by 2% compared 6 and 15 MV‐SA.
Furthermore, it has been reported that dose ≥78 Gy to 50% of
the bladder volume results in the development of GU complica-
tions,32 which was not exceeded by any of the plans in this study. It
is important to note here that maximum dose to bladder exceeded
65 Gy, especially in the overlapping region of bladder and the PTV,
TA B L E 10 The average difference, Davg (%), of dosimetric
parameters between 6 MV‐PA and MEPAs (6/15 MV 1:1 weighted),










PTV Min dose (%) 2.4 ± 3.0 2.7 ± 2.6
Max dose (%) 0.4 ± 1.7 −0.5 ± 1.4
Mean dose (%) 0.1 ± 0.3 0.7 ± 0.5
HI (%) −11.2 ± 11.0 −6.9 ± 10.0
CN (%) −6.8 ± 4.8 −6.4 ± 4.7
Bladder Max dose (%) 0.1 ± 1.3 0 ± 1.8
Mean dose (%) 14.0 ± 7.9 14.0 ± 7.6
V70Gy (%) 15.6 ± 13.7 15.9 ± 11.4
V60Gy (%) 14.7 ± 11.8 16.1 ± 12.1
V45Gy (%) 15.9 ± 11.3 18.1 ± 10.3
V15Gy (%) 10.6 ± 9.0 15.7 ± 12.1
Rectum Max dose (%) 0.5 ± 2.2 0.1 ± 1.6
Mean dose (%) 12.11 ± 9.0 13.9 ± 9.1
V70Gy (%) 26.6 ± 19.5 23.8 ± 18.8
V60Gy (%) 24.2 ± 21.5 23.7 ± 19.9
V45Gy (%) 17.3 ± 19.4 17.1 ± 18.1
V15Gy (%) 4.5 ± 3.7 6.3 ± 3.7
Left femur Mean dose (%) −26.0 ± 55.7 −26.1 ± 43.1
Right femur Mean dose (%) −24.7 ± 40.1 −30.0 ± 43.5
MUs 12.6 ± 8.4 −9.4 ± 15.0
VnGy, in terms of data, represents the percentage of structure volume
receiving n Gy or more. D6MVAvg and D
15MV
Avg were calculated using Eq. (3).
PTV: planning target volume.
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which involves the risk of Grade 3 toxicity as a late response.29
However, this was mainly due to not including maximum bladder
dose constraints during optimization for any of the three techniques.
This was because it is considered a strict constraint — required to
be achieved by every single voxel of a structure, which, in turn,
would require us to change the optimization parameters and opti-
mize the plans individually. Instead, the goal was to optimize all the
plans with a ﬁxed optimization setup to highlight superiority among
different techniques. In terms of prostate motion, a greater prostate
motion has been reported to occur in anterior and posterior direc-
tion than lateral direction.33 Furthermore, it has been demonstrated
that intrafraction prostate motion from breathing is a major cause of
prostate positional variation.34 Although lower MUs would reduce
the total treatment time resulting in lower probability of such organ
motion, the total treatment time for MEPAs technique, regardless of
the lower MUs, may not be reduced signiﬁcantly as two different
energies need to be moded up at the console for each treatment
fraction.
Historically, patient separation in anterior posterior direction
greater than 20 cm were considered as a threshold for using higher
photon energy,35 the mean AP separation in our study was ~23 cm.
The rationale behind using the lowest clinical range (6 MV) to the
highest clinical range (15 MV) was to exploit the maximum differ-
ence in dose deposition. Both MEPAs techniques in this study
involved 15 MV, which raises a question of additional dose depos-
ited by photo‐neutrons produced in the linac head. This may be of
some concern for MEPA (6/15 MV 1:2 weighted) technique as 2/3
of the PD is delivered by 15 MV beam. One study on the measure-
ment of photo‐neutron dose at isocenter from an 18 MV linac
showed that the total neutron equivalent dose is two to three orders
of magnitude smaller than the photon dose delivered to the
patient.36 Nonetheless the amount of neutron dose in the vicinity of
the patient should not be neglected, which is one of the limitations
of this study. Therefore, prior to clinically employing MEPA with
15 MV and higher, additional risks of secondary cancers due to
photo‐neutrons should be considered. Furthermore, mixed energies
VMAT involving higher energy would not be recommended for
patients with pacemakers as it can result in the device malfunction.37
Since the neutron production for higher energy (>10 MV) in FFF
mode is reduced as much as 70%,29 similar mixed energy technique
for ﬂattening ﬁlter free (FFF) modality would be an interesting topic
for future investigation, though clinical use of FFF modality is cur-
rently limited to ≤10 MV.
Another limitation of our work is the same set of optimization
parameters including priority weighting factors used for all the
patients in Part 1 and 2 of this study. Our rationale behind maintain-
ing same parameter set was to ensure that the differences were only
due to energy and dose weighting selection in Part 1, and energy
F I G 5 . The dose distribution of a 6 MV‐
PA, a 15 MV‐PA, and a MEPA (6/15 MV
1:1 weighted) plan for one representative
case in sagittal views.
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selection in Part 2 of this study. This approach permitted reliable
comparison to justify a superior treatment planning technique for
each part of this study. However, in practice, the optimization
parameters of MEPAs plans speciﬁc to individual patients and corre-
sponding treatment planning goals can further improve quality of
MEPAs plans including reductions in maximum doses to bladder and
femoral heads.
In terms of implications of MEPAs technique to clinical work‐
ﬂow, determining an ideal proportion of PD dedicated to each of the
selected energies would be crucial to achieve desired dosimetric out-
come. However, given that current TPS does not allow the optimiza-
tion of proportion of PD dedicated to each energy for a mixed
energy VMAT plan, determining an ideal proportion of PD dedicated
to each energy in MEPAs plan would require a trial and error pro-
cess, especially with different combination of energies and dose
weighting factors. For instance, MEPAs can also be used in combina-
tion of 6 and 10 MV, which has less concerns of production of sec-
ondary neutrons in comparison to the combination of energies used
in this study, 6 and 15 MV. We used the lowest and highest clinical
MV range to exploit the maximum difference in dose deposition.
Nevertheless, once established, MEPAs can easily be implemented
for post optimization stages (i.e, patient speciﬁc QA) as the patient
speciﬁc QA for MEPAs plans can be performed similarly to that of a
single‐energy VMAT plans. This study was based on comparisons of
TPS generated dosimetric outcomes. Any quality assurance of these
plans was not considered as it was beyond the scope of this work.
Finally, the radiobiological impact of any of the techniques used in
this study was not investigated.
The TPS used in this study (RapidArc™, Eclipse, Palo Alto, CA,
USA) does not allow optimization of a single plan with two different
energies. Therefore, a composite plan was generated by summing a
lower energy and a higher energy plan. Beside the TPS used in this
study, the RayStation™ (Raysearch Laboratories, Stockholm, Sweden)
and the Monaco™ (Elekta, Stockholm, Sweden) are two major treat-
ment planning systems that are currently being used to optimize
VMAT treatment plans. However, to our knowledge, no current
treatment planning system, including the one used in this study,
allows simultaneous optimization of two different energies. The cur-
rent study, thus, involved the manual selection of dose weighting
per energy to achieve the desire dosimetric outcome. An algorithm
that simultaneously optimizes for both energies is necessary as it
will generate a plan with an optimal proportion of PD dedicated to
each energy, which, in turn, will further improve the quality of a
mixed energy VMAT plan. While it was beyond the scope of this
work to investigate the most suitable TPS for MEPAs technique, it
would be interesting to investigate MEPAs on RayStation™, which
utilizes multicriteria optimization where the user navigates through
many pareto optimal plans to arrive at a plan with desired dosimet-
ric tradeoffs. However, the dosimetric comparisons between two
plans may not be suitable for RayStation™ as due to selection of
best possible tradeoff between different dose‐volume objectives of
various structures, the parameters may not remain same in the two
plans.
5 | CONCLUSIONS
This study investigated the potential scope of using MEPAs VMAT
technique to treat prostate cancer compared to single‐energy
VMAT techniques. In Part 1 of this study, MEPAs (6/15 MV 1:2
weighted) plans were found to be superior in sparing bladder and
rectum, but resulting in slightly reduced target homogeneity com-
pared to either 6 and 15 MV‐SA plans. In Part 2 of this study, the
impact of multiple energies alone was investigated by equally
weighting both 6 and 15 MV in MEPAs (6/15 MV 1:1 weighted)
and comparing with single‐energy partial arcs (6 and 15 MV‐PA).
MEPAs (6/15 MV 1:1 weighted) plans resulted in improved target
dose conformity and, lower doses to bladder and rectum compared
to 6 and 15 MV‐PA. In both parts, however, mixed energy VMAT
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